Welcome to our dedicated page for Sight Sciences SEC filings (Ticker: SGHT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sight Sciences, Inc. (Nasdaq: SGHT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As an eyecare technology company focused on interventional glaucoma and dry eye devices, Sight Sciences uses SEC reports to communicate financial results, capital arrangements, and key corporate developments.
Investors can review Form 8-K filings where the company reports quarterly and year-to-date financial highlights, raises or updates revenue and adjusted operating expense guidance, and describes restructuring plans intended to reduce operating expenses and improve cost efficiencies. Other 8-Ks detail amendments to the company’s senior secured term loan facility with Hercules Capital, including changes to the interest-only period and tranche availability.
Filings also disclose material corporate events such as workforce reductions, executive transitions, and board changes. For example, the company has reported promotions of senior executives, entry into amended and restated employment agreements, and the resignation of directors, along with related compensation and severance terms.
These SEC documents complement the company’s press releases on clinical and reimbursement milestones for its OMNI® Surgical System, SION® Surgical System, and TearCare® System. On Stock Titan, users can access real-time updates from EDGAR and use AI-powered summaries to quickly understand the main points of lengthy filings, including quarterly (10-Q) and annual (10-K) reports when available, as well as Form 4 insider transaction reports.
AI-generated overviews help explain complex sections of Sight Sciences’ filings in plain language, highlight changes in guidance or capital structure, and point out disclosures that may be relevant to the company’s Surgical Glaucoma and Dry Eye segments. This allows readers to navigate detailed regulatory documents more efficiently while focusing on the aspects of SGHT’s business that matter most to them.
SGHT submitted a Form 144 notice disclosing proposed sales of Common Stock. The filing lists 576 shares associated with 03/30/2026 (restricted stock vesting) and 2,293 shares associated with 03/31/2026 (restricted stock vesting). The filing also reports 619 shares sold on 01/06/2026 by Brenton Taylor.
Sight Sciences, Inc. announced that the U.S. District Court for the District of Delaware issued an order preserving a jury’s verdict that Alcon willfully infringed three Sight Sciences glaucoma patents. The order awards $34 million in past monetary damages, plus supplemental damages and interest, and grants an ongoing 10% royalty on Hydrus Microstent revenue through November 10, 2028, when the last asserted patent expires. A final judgment will be entered after supplemental damages and pre-judgment interest are calculated and remains subject to appeal by Alcon. Parallel ex parte reexaminations at the USPTO could affect Sight Sciences’ ability to collect if adverse outcomes become final before the litigation is finally resolved in the company’s favor. Sight Sciences expects to record a $5.4 million success fee payable to its litigation counsel in operating expenses, which it plans to exclude from non-GAAP adjusted operating expenses.
Sight Sciences, Inc. is an eyecare technology company focused on interventional treatments for glaucoma and dry eye disease. It develops devices designed to restore the eye’s natural drainage and tear-film function, targeting large but under-served markets.
The company’s interventional glaucoma business centers on the OMNI Surgical System and the SION Surgical Instrument, which enable minimally invasive glaucoma surgery in both cataract-combination and standalone procedures. For dry eye, its TearCare system delivers controlled heat and manual gland expression to treat meibomian gland disease, supported by randomized clinical trials such as OLYMPIA and SAHARA and health-economic studies showing potential cost savings versus prescription drops.
Sight Sciences emphasizes clinical evidence, reimbursement access, and specialized sales teams in the U.S. and select international markets. As of June 30, 2025, non-affiliate market value was about $153.6 million, and 54,005,984 common shares were outstanding as of February 26, 2026.
Sight Sciences reported mixed 2025 results with improving profitability trends and issued 2026 guidance. Full-year 2025 revenue was $77.4 million, down 3% from 2024, as Interventional Glaucoma revenue held flat at $75.7 million while Interventional Dry Eye fell to $1.6 million.
Fourth-quarter 2025 revenue was $20.4 million, up 7%, with total gross margin at 87%. Full-year gross margin was 86%. Operating expenses fell 13% to $103.8 million and net loss narrowed to $38.4 million, or $0.74 per share, from $51.5 million.
Cash and cash equivalents were $92.0 million and long-term debt $40.0 million as of December 31, 2025, after $28.4 million of cash use in 2025. For 2026, the company guides revenue to $82–$88 million and adjusted operating expenses to $93–$96 million.
Sight Sciences, Inc. Chief Technology Officer David Badawi exercised previously granted stock options for 21,270 shares of common stock at $0.23 per share. These options were awarded under the company’s equity incentive plan and fully vested by January 1, 2020.
Following this option exercise, Badawi directly holds a total of 1,998,458 common share equivalents, consisting of 1,795,520 shares of common stock and 202,938 shares that will be received upon the future vesting and settlement of restricted stock units.
Sight Sciences, Inc. disclosed that Chief Technology Officer and director David Badawi received a grant of 64,915 restricted stock units (RSUs) on February 3, 2026 under the company’s 2021 Incentive Award Plan. The grant value is based on $420,000 divided by the closing price of Sight Sciences common stock on the grant date.
The RSUs vest in 16 equal quarterly installments from March 31, 2026 through December 31, 2029, contingent on his continued service. After this grant, Badawi beneficially owns 1,977,188 common shares, including 1,774,250 shares and 202,938 unvested RSUs that may settle into additional shares over time.
Sight Sciences, Inc. reported that Chief Legal Officer Jeremy B. Hayden received an award of 115,920 restricted stock units (RSUs) of common stock on February 3, 2026 under the company’s 2021 Incentive Award Plan, at a price of $0 per share.
The RSUs vest in 16 equal quarterly installments from March 31, 2026 through December 31, 2029, contingent on his continued service. Each RSU converts into one share of common stock. After this grant, Hayden beneficially owns 383,531 shares, including 75,562 shares of common stock and 307,969 shares underlying unvested RSUs.
Sight Sciences Chief Operating Officer Alison Bauerlein received a grant of 127,512 restricted stock units (RSUs) of common stock on February 3, 2026. The RSU award size is based on $825,000 divided by the closing price of the stock on the grant date.
The RSUs vest in 16 equal quarterly installments from March 31, 2026 through December 31, 2029, contingent on continued service. After this grant, Bauerlein beneficially owns 727,495 shares of common stock, including 135,620 shares and 591,875 shares underlying unvested RSUs.
Sight Sciences reported that President and CEO Paul Badawi received a grant of 154,560 restricted stock units on February 3, 2026 under the company’s 2021 Incentive Award Plan. The grant’s size is based on a $1,000,000 value divided by the stock’s closing price on the grant date.
The RSUs vest in 16 equal quarterly installments from March 31, 2026 through December 31, 2029, contingent on Badawi’s continued service. Following this award, he beneficially owns 6,180,400 shares of common stock, including 662,622 shares underlying unvested RSUs.
Sight Sciences Chief Financial Officer James Rodberg received a grant of 86,940 restricted stock units (RSUs) of common stock on February 3, 2026 under the company’s 2021 Incentive Award Plan. The grant value is set at $562,500, divided by the stock’s closing price on the grant date.
The RSUs vest in 16 equal quarterly installments from March 31, 2026 through December 31, 2029, contingent on Rodberg’s continued service. Each RSU converts into one share of common stock upon vesting. After this award, he beneficially owns 238,170 shares, including 198,719 unvested RSUs and 39,451 vested shares.